Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Vivoryon Therapeutics N.V., NL00150002Q7

Vivoryon Therapeutics N.V., NL00150002Q7

21.09.2021 - 07:03:28

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress

The Company did not generate any licensing revenues in the reporting period. Revenues deriving from the strategic regional licensing partnership with Simcere will be recognized starting in the third quarter of 2021.

Net loss of the period was EUR 11,671 k compared to EUR 7,572 k in the first half of 2020. The Company held EUR 19,832 k in cash and cash equivalents as of June 30, 2021, compared to EUR 26,306 k as of December 31, 2020.

Conference Call and Webcast Vivoryon will host a conference call and webcast today, September 21, 2021, at 3:00 pm CEST / 9:00 am EDT. A Q&A session will follow the presentation of the half year results.

Please dial one of the following access numbers: From Germany: +49 69 201 744 220 From The Netherlands: +31 207 168 020 From UK: +44 20 30 092 470 From the US: +18 774 230 830PIN Code: 53651371#

Please dial in ten minutes prior to commencement. A live webcast and slides will be made available at: www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/.

Approximately one day after the call, a slide-synchronized audio replay of the conference will be available on: www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/.

The statement for the first six months of 2021 is available on the Company's website www.vivoryon.com/investors-news/financial-information.Vivoryon Therapeutics N.V. Condensed Statements of Profit or Loss and Other Comprehensive Income

? For the six months ended June 30, (in EUR thousand, except for share data) 2021 2020 ? ? ? Operating Expenses ? ? Research and development expenses 9,456 6,380 General and administrative expenses 2,337 1,138 Total Operating Expenses 11,793 7,518 Other income (5) (38) Operating loss 11,788 7,480 Finance income (219) - Finance expenses 102 92 Finance result (117) 92 Loss for the Period 11,671 7,572 ? ? ? Share Information ? ? Weighted average number of shares outstanding 19,975,482 19,975,482 Loss per share (basic/diluted) (0.58) (0.38) ? ? ? Loss for the Period 11,671 7,572 Items not to be reclassified subsequently to profit or loss: ? ? Remeasurement of the net defined benefit pension liability - 20 Total Comprehensive Loss 11,671 7,592 ? ? ? ?

Vivoryon Therapeutics N.V. Condensed Statements of Financial Position

(in EUR thousand) June 30,2021 December 31,2020 ? ? ? ASSETS ? ? Non-current assets ? ? Property, plant and equipment 343 390 Intangible assets 553 565 Financial assets 14 3 Total non-current assets 910 958 Current assets ? ? Other assets 1,631 2,466 Financial assets 667 21 Cash and cash equivalents 19,832 26,306 Total current assets 22,130 28,793 TOTAL ASSETS 23,041 29,751 ? ? ? EQUITY AND LIABILITIES ? ? Equity ? ? Share capital 19,975 19,975 Share premium 82,143 82,143 Other capital reserves 5,324 4,404 Accumulated other comprehensive loss (655) (655) Accumulated deficit (91,316) (79,646) Total equity 15,471 26,221 Non-current liabilities ? ? Post-employment benefits 1,940 1,981 Provisions long-term 12 - Lease liabilities long-term 179 224 Trade payables 168 - Total non-current liabilities 2,299 2,205 Current liabilities ? ? Provisions 35 47 Trade payables 4,988 911 Lease liabilities 91 90 Other liabilities 157 276 Total current liabilities 5,271 1,325 Total Liabilities 7,570 3,530 TOTAL EQUITY AND LIABILITIES 23,041 29,751 ? ? ? ?

Vivoryon Therapeutics N.V. Statements of Changes in Shareholders' Equityfor the six months ended June 30, 2021 and 2020

(in EUR thousand, except for share data) Shares outstanding Share capital Share premium Other capital reserves Accumulated deficit Accumu-lated other compre-hensive loss Total equity ? ? ? ? ? ? ? ? Balance as of January 1, 2021 19.975.482 19.975 82.143 4.404 (79.646) (655) 26.221 Loss for the period - - - - (11,671) - (11,671) Remeasurement of the net defined benefit pension liability - - - - - - - Total comprehensive loss - - - - (11,671) - (11,671) Contributions ? ? ? ? ? ? ? Equity-settled share-based payments - - - 920 - - 920 Total Contributions - - - 920 - - 920 Balance as of June 30, 2021 19,975,482 19,975 82,143 5,325 (91,317) (655) 15,471 ? ? ? ? ? ? ? ? Balance as of January 1, 2020 19,975,482 19,975 82,143 4,245 (63,136) (562) 42,665 Loss for the period - - - - (7,572) - (7,572) Remeasurement of the net defined benefit pension liability - - - - - (20) (20) Total comprehensive loss - - - - (7,572) (20) (7,592) Contributions ? ? ? ? ? ? ? Equity-settled share-based payments - - - 3 - - 3 Total Contributions - - - 3 - - 3 Balance as of June 30, 2020 19.975.482 19,975 82,143 4,247 (70,708) (582) 35,075 ? ? ? ? ? ? ? ? ?

Vivoryon Therapeutics N.V. Condensed Statements of Cash Flows for the six monthsended June 30, 2021 and 2020

(in EUR thousand) For the six months ended June 30, 2021 (unaudited) For the six months ended June 30, 2020 (unaudited) ? ? ? Operating activities ? ? Loss for the period (11,671) (7,572) Adjustments for: ? ? Finance result (117) 92 Depreciation and amortization of property, plant, equipment, right-of-use assets and intangible assets 83 67 Share-based payment expense 920 3 Other non-cash adjustments (9) 0 Changes in: ? ? Other assets 834 1,105 Other financial assets (660) 309 Pension liabilities (40) (40) Trade and other payables 4,125 (313) Interest paid (9) (4) Interest received 4 - Net cash used in operating activities (6,540) (6,353) Investing activities ? ? Purchase of intangible assets, laboratory and office equipment (24) (574) Net cash from/ (used in) investing activities (24) (574) Financing activities ? ? Repayment of lease liabilities (45) (45) Net cash from/ (used in) financing activities (45) (45) Net decrease in cash and cash equivalents (6,609) (6,972) Effect of exchange rate changes on cash and cash equivalents 135 (81) Cash and cash equivalents at beginning of period 26,306 41,524 Cash and cash equivalents at end of period 19,832 34,471 ? ? ? ?

For more information, please contact: Investor ContactVivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Tel: +49 (0)345 555 99 30 Email: IR@vivoryon.com

Media ContactTrophic Communications Valeria Fisher / Sophia Hergenhan Tel: +49 175 8041816 Email: vivoryon@trophic.euAbout Vivoryon Therapeutics N.V.

Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com

Forward-Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

Additional features:File: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress

21.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Vivoryon Therapeutics N.V. Weinbergweg 22 06120 Halle/Saale

Germany Phone: +49 (0)345 555 9900 Fax: +49 (0)345 555 9901 E-mail: contact@vivoryon.com Internet: www.vivoryon.com ISIN: NL00150002Q7 WKN: A2QJV6 Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam EQS News ID: 1234753 ? End of News DGAP News Service

1234753??21.09.2021?

@ dgap.de